Silver Book Fact

Macugen to treat wet age-related macular degeneration (AMD)

A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.

Gragoudas, Evangelos S., Anthony P. Adamis, Emmett T. Cunningham, Matthew Feinsod, and David R. Guyer. Pegaptanib for Neovascular Age-Related Macular Degeneration. NEJM. 2004; 351(27): 2805-16. http://content.nejm.org/cgi/content/abstract/351/27/2805

Reference

Title
Pegaptanib for Neovascular Age-Related Macular Degeneration
Publication
NEJM
Publication Date
2004
Authors
Gragoudas, Evangelos S., Anthony P. Adamis, Emmett T. Cunningham, Matthew Feinsod, and David R. Guyer
Volume & Issue
Volume 351, Issue 27
Pages
2805-16
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Impact of a healthy lifestyle on age-related macular degeneration (AMD)
    A study exploring the impact of a healthy lifestyle on age-related macular degeneration (AMD) found that women whose diets were the healthiest (scored on the 2005 Healthy Eating Index) had…  
  • Nearly 50% of diabetic retinopathy patients who received ranibizumab–an anti-VEGF drug–experienced substantial visual improvement after a year of injections  
  • Supplementation with lutein increases macular pigment optical density by 27%; which is correlated with benefits in visual function.  
  • Lucentis to treat wet age-related macular degeneration (AMD)
    An FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)–ranibizumab (Lucentis)–maintained vision in 95% of clinical trial participants and improved vision by 15 or more letters in approximately 25%…  
  • DR Treatment Reduced Risk of Blindness
    Appropriate treatment can reduce the risk of blindness or moderate vision loss from DR by more than 90%.